Dataset from A Randomized, Multi-center, Open-label, Cross-over Study Comparing Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler Versus the BREEZHALER Dry Powder Inhaler, in Adult Participants With Mild to Moderate Asthma

This study aims to provide data in adult participants with mild to moderate asthma to assist
healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER
DPIs, by comparing the incidence of critical and overall errors, participant preference,
willingness to continue with the inhaler and time to correct use. ELLIPTA® is a registered
trademark of GlaxoSmithKline (GSK) and BREEZHALER® is a registered trademark of Novartis.